Access cutting-edge systemic sclerosis cutaneous lupus e myopathies systemic lupus erythematosus treatment through this phase 3 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Los Angeles location
Preparing your pre-screening questions…
Access systemic sclerosis cutaneous lupus e myopathies systemic lupus erythematosus specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related systemic sclerosis cutaneous lupus e myopathies systemic lupus erythematosus treatment provided free
Check if you qualify for this systemic sclerosis cutaneous lupus e myopathies systemic lupus erythematosus clinical trial in Los Angeles, CA
No-Cost Study Care
Local to Los Angeles
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator, while monitoring safety and tolerability. Study details include: * Participants can transition in ROSY-S once they complete their participation in the parent study and should have received at least one dose of anifrolumab in the parent study. Participants with a treatment gap from parent studies and/or who are on compassionate use are eligible to rollover to ROSY-S study. * The earliest that the Enrolment Visit may occur is at the time of the last visit of the parent study (ie, completion of the parent study's final safety follow-up visit). All required assessments from the safety follow-up visit of the parent study must be completed before the Enrolment Visit of ROSY-S study. * The participants will continue to receive anifrolumab the same way they received it in the parent trial * A participant is considered to have completed the study when they meet one of the discontinuation criteria. * Safety will be monitored throughout the study. Both serious and nonserious AEs will be collected up to 12 weeks after the last dose of anifrolumab and will be reported as part of the primary safety endpoint.
Sponsor: AstraZeneca
Yes, this clinical trial (NCT07691970) has an active research site in Los Angeles, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for systemic sclerosis cutaneous lupus e myopathies systemic lupus erythematosus treatment options in Los Angeles, CA, this clinical trial (NCT07691970) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced systemic sclerosis cutaneous lupus e myopathies systemic lupus erythematosus specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all systemic sclerosis cutaneous lupus e myopathies systemic lupus erythematosus clinical trials near you to find additional studies recruiting in your area.
See all heart attack clinical trials recruiting in Los Angeles — not just this study.
Browse Heart Attack Trials in Los Angeles →